Wei-Kuang Yu

Dr. Wei-Kuang Yu

Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2014 in Japanese Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
WYWei-Kuang Yu
Wei-Kuang Yu
SKShu-Ching Kao
Shu-Ching Kao
CYChing-Fen Yang
Ching-Fen Yang
FLFenq-Lih Lee
Fenq-Lih Lee
Chieh-Chih TsaiChieh-Chih Tsai
Chieh-Chih Tsai

1 January 2018 in Taiwan Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
WYWei-Kuang Yu
Wei-Kuang Yu
Chieh-Chih TsaiChieh-Chih Tsai
Chieh-Chih Tsai
SKShu-Ching Kao
Shu-Ching Kao
CLCatherine Jui-Ling Liu
Catherine Jui-Ling Liu
Immunoglobulin G4-related disease (IgG4-RD) is a recently recognized inflammatory disease of unknown etiology. It characterized by distinctive histopathological appearance of dense IgG4-positive lymphoplasmacytic infiltrates, storiform fibrosis, and obliterative phlebitis in one or more organs, simultaneously or subsequently. In cases of ocular adnexal involvement, unique clinicohistopathological features were delineated by recent studies, and IgG4-related ophthalmic disease (IgG4-ROD) is generally recognized as the disease name. A significant proportion of previous labeled idiopathic orbital inflammations and Mikulicz's disease are now consistent with a diagnosis of IgG4-ROD. Increasing studies have accumulated regarding its epidemiology, diagnosis, clinical features, treatment, and the association between lymphoma. In this review, we summarize our present understanding of IgG4-ROD.

8 September 2014 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
WYWei-Kuang Yu
Wei-Kuang Yu
YCY.‐T. Chen
Y.‐T. Chen
SWS.‐J. Wang
S.‐J. Wang
SKS.‐C. Kuo
S.‐C. Kuo
BSB.‐C. Shia
B.‐C. Shia
CLCatherine Jui-Ling Liu
Catherine Jui-Ling Liu

23 December 2015 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
YHYu-Yun Huang
Yu-Yun Huang
WYWei-Kuang Yu
Wei-Kuang Yu
Chieh-Chih TsaiChieh-Chih Tsai
Chieh-Chih Tsai
SKShu-Ching Kao
Shu-Ching Kao
HKHui-Chuan Kau
Hui-Chuan Kau
CLCatherine Jui-Ling Liu
Catherine Jui-Ling Liu
Aims To compare the clinical features and treatment outcome between lacrimal plug-related canaliculitis and primary canaliculitis. Methods Patients with plug-related canaliculitis and primary canaliculitis between 2007 and 2014 in a medical centre were collected. Charts were reviewed for clinical features, microbiological profiles, time lapse between plug insertion and symptom onset, type of plug and outcomes. Results Of 76 eligible cases collected, 13 were plug-related canaliculitis and 63 were primary canaliculitis. The most common presenting symptom was discharge in both groups (85% and 79%, respectively). The average time interval from plug insertion to symptoms onset was 5.5 years. Most canaliculitis developed in women, especially for plug-related canaliculitis, when compared with primary canaliculitis (100% vs 65.1%; p=0.015). The most common isolated microorganism was Pseudomonas aeruginosa in plug-related canaliculitis (46%) and Streptococcus in primary canaliculitis (28%), respectively. Isolation of Pseudomonas was significantly higher in plug-related canaliculitis than in primary canaliculitis (46% vs 12%; p=0.029). Most plug-related canaliculitis resolved after removal of plugs by canaliculotomy (12 cases, 93%). Most identified plug was SmartPlug (seven cases), followed by EaglePlug (two cases) and Herrick Lacrimal Plug (two cases). There was no recurrence in patients with plug-related canaliculitis, however, recurrence developed in seven patients (11%) with primary canaliculitis. Conclusions In comparison with primary canaliculitis, plug-related canaliculitis appear to be more prevalent in women and show a different microbiological profile. Retrieval of infected plug by canaliculotomy and adequate antibiotics can achieve a good outcome. Long-term follow-up is required because canaliculitis may develop several years after plug insertion.

29 May 2020 in Journal of the Chinese Medical Association
Verified
Journal Article
Open access
DHDe-Kuang Hwang
De-Kuang Hwang
WYWei-Kuang Yu
Wei-Kuang Yu
TLTai-Chi Lin
Tai-Chi Lin
SCShih-Jie Chou
Shih-Jie Chou
AYAliaksandr Yarmishyn
Aliaksandr Yarmishyn
YJYing-Chun Jheng
Ying-Chun Jheng
Background: Diabetic macular edema (DME) is a sight-threatening condition that needs regular examinations and remedies. Optical coherence tomography (OCT) is the most common used examination to evaluate the structure and thickness of the macula, but the software in the OCT machine does not tell the clinicians whether DME exists directly. Recently, artificial intelligence (AI) is expected to aid in diagnosis generation and therapy selection. We thus develop a smartphone-based offline AI system that provides diagnostic suggestions and medical strategies through analyzing OCT images from diabetic patients at the risk of developing DME. Methods: DME patients receiving treatments in 2017 at Taipei Veterans General Hospital were included in this study. We retrospectively collected the OCT images of these patients from January 2008 to July 2018. We established the AI model based on MobileNet architecture to classify the OCT images conditions. The confusion matrix has been applied to present the performance of the trained AI model. Results: Based on the convolutional neural network with the MobileNet model, our AI system achieved a high DME diagnostic accuracy of 90.02%, which is comparable to other AI systems such as InceptionV3 and VGG16. We further developed a mobile-application based on this AI model available at https://aicl.ddns.net/DME.apk. Conclusion: We successful integrated an AI model into the mobile device to provide an offline method to provide the diagnosis for quickly screening the risk of developing DME. With the offline property, our model could help those nonophthalmological healthcare providers in offshore islands or underdeveloped countries.

Verified
Journal Article
Open access
PDF file
WYWei-Kuang Yu
Wei-Kuang Yu
Wei-Lun HwangWei-Lun Hwang
Wei-Lun Hwang
YWYi-Chuan Wang
Yi-Chuan Wang
Chieh-Chih TsaiChieh-Chih Tsai
Chieh-Chih Tsai
YWYau-Huei Wei
Yau-Huei Wei
Orbital fibrosis, a hallmark of tissue remodeling in Graves’ ophthalmopathy (GO), is a chronic, progressive orbitopathy with few effective treatments. Orbital fibroblasts are effector cells, and transforming growth factor β1 (TGF-β1) acts as a critical inducer to promote myofibroblast differentiation and subsequent tissue fibrosis. Curcumin is a natural compound with anti-fibrotic activity. This study aims to investigate the effects of curcumin on TGF-β1-induced myofibroblast differentiation and on the pro-angiogenic activities of orbital fibroblasts. Orbital fibroblasts from one healthy donor and three patients with GO were collected for primary cell culture and subjected to myofibroblast differentiation under the administration of 1 or 5 ng/mL TGF-β1 for 24 h. The effects of curcumin on TGF-β1-induced orbital fibroblasts were assessed by measuring the cellular viability and detecting the expression of myofibroblast differentiation markers, including connective tissue growth factor (CTGF) and α-smooth muscle actin (α-SMA). The pro-angiogenic potential of curcumin-treated orbital fibroblasts was evaluated by examining the transwell migration and tube-forming capacities of fibroblast-conditioned EA.hy926 and HMEC-1 endothelial cells. Treatment of orbital fibroblasts with curcumin inhibited the TGF-β1 signaling pathway and attenuated the expression of CTGF and α-SMA induced by TGF-β1. Curcumin, at the concentration of 5 μg/mL, suppressed 5 ng/mL TGF-β1-induced pro-angiogenic activities of orbital fibroblast-conditioned EA hy926 and HMEC-1 endothelial cells. Our findings suggest that curcumin reduces the TGF-β1-induced myofibroblast differentiation and pro-angiogenic activity in orbital fibroblasts. The results support the potential application of curcumin for the treatment of GO.